Dundas Partners LLP Makes New Investment in LeMaitre Vascular, Inc. $LMAT

Dundas Partners LLP acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,660 shares of the medical instruments supplier’s stock, valued at approximately $221,000.

A number of other hedge funds have also made changes to their positions in LMAT. Victory Capital Management Inc. lifted its position in LeMaitre Vascular by 45.9% in the first quarter. Victory Capital Management Inc. now owns 79,871 shares of the medical instruments supplier’s stock worth $6,701,000 after purchasing an additional 25,133 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth $728,000. Avantax Advisory Services Inc. lifted its holdings in shares of LeMaitre Vascular by 1.5% in the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 229 shares during the period. Cetera Investment Advisers boosted its stake in LeMaitre Vascular by 209.6% during the first quarter. Cetera Investment Advisers now owns 8,522 shares of the medical instruments supplier’s stock valued at $715,000 after buying an additional 5,769 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in LeMaitre Vascular by 1.3% during the first quarter. Federated Hermes Inc. now owns 39,504 shares of the medical instruments supplier’s stock valued at $3,314,000 after buying an additional 518 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

LMAT has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Finally, Barrington Research reiterated an “outperform” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $100.20.

LeMaitre Vascular Stock Up 4.1%

LMAT stock opened at $87.93 on Friday. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The company’s 50 day simple moving average is $88.13 and its 200-day simple moving average is $86.98. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The firm has a market capitalization of $1.99 billion, a P/E ratio of 42.68, a P/E/G ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.05. The firm had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 4th. Investors of record on Thursday, November 20th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio is currently 34.48%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.